Protalix files BLA to compete with Sanofi Genzyme; Rallybio collects another Alexion alum
→ Protalix BioTherapeutics has filed a BLA for their Fabry Disease treatment, pegunigalsidase alfa. The drug is a recombinant enzyme grown in plant cell cultures and designed to supplement the lysosomal enzyme that is deficient in patients with the genetic disorder. Chiesi Global Rare Diseases has signed up to commercialize the drug, in a deal that’s worth up to $760 million. A phase III study showed the Israeli biotech’s drug led to much higher concentration of enzyme than Fabrazyme, the longtime standard-of-care from Sanofi Genzyme.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.